The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed/platinum therapy.
Dean Anthony Fennell
Honoraria - Verastem
Paul Baas
Honoraria - Verastem
Hedy Lee Kindler
Honoraria - Verastem
Lee M. Krug
Honoraria - Verastem
Anna Nowak
Honoraria - Verastem
Marjorie Zauderer
Honoraria - Verastem
Richard J. Gralla
Honoraria - Verastem
Mitchell Keegan
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Joanna Horobin
Employment or Leadership Position - Verastem
Stock Ownership - Verastem